You just read:

Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)

News provided by

Janssen Research & Development, LLC

Dec 11, 2017, 08:30 ET